Form 4: United Therapeutics Director Christopher Patusky Reports Acquisition of Stock Options and Restricted Stock Units

Director Christopher Patusky reports acquisition of stock options and restricted stock units in United Therapeutics Corp.

Summary

• On July 25, 2024, Christopher Patusky, a director of United Therapeutics Corporation, reported the acquisition of 1,440 stock options and 590 restricted stock units (RSUs).
• The stock options have an exercise price of $336.37 and vest on July 25, 2025, expiring on July 25, 2034.
• The RSUs vest on July 25, 2025, and each represents the right to receive one share of United Therapeutics Corporation common stock.
• Following the transaction, Patusky directly owns 1,440 shares of common stock and 590 derivative securities.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing, and the sentiment is neutral as it simply reports transactions.

Positives

• The acquisition of stock options and RSUs could align the director's interests with those of the shareholders, incentivizing performance and value creation.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Comparison to Industry Standards

• Stock option and RSU grants are common forms of executive compensation in the biotechnology and pharmaceutical industries.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize similar equity-based compensation plans to incentivize their directors and officers.
• The vesting schedules and terms of these grants are generally in line with industry standards, typically vesting over a oneto four-year period.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment as it indicates the director's belief in the company's future prospects.

Key Dates